Radiopharmaceutical probe developer Neoprobe reported fourth-quarter revenues $1.9 million, up 13% compared with the $1.7 million turned in during the fourth quarter of 2002. For the period (end-December 31), the Dublin, OH-based firm had a net loss of $582,000, compared with a net loss of $165,000 a year ago.
For the year, Neoprobe had revenues of $6.5 million, up 32% compared with the $4.9 million booked in 2002. The company had a net loss of $1.8 million, compared with a net loss of $3 million in 2002. The 2003 operating results reflect continued investment in the development and commercialization of its Quantix blood flow measurement technology, according to Neoprobe.
By AuntMinnie.com staff writersMarch 9, 2004
Related Reading
Neoprobe hires Linder, October 27, 2003
Neoprobe gets go-ahead for Quantix/OR, September 9, 2003
Neoprobe continues to trim losses, increase revenue, July 31, 2003
Neoprobe cuts loss, May 8, 2003
Neoprobe begins delivering Quantix/OR, April 28, 2003
Copyright © 2004 AuntMinnie.com
